Loading…
Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus
We explored the effectiveness of COVID-19 vaccines in preventing reinfection in the Republic of Cyprus. This was a matched case–control study (1:2). Cases were adults with a first episode of SARS-CoV-2 infection in 2020 and a second episode (i.e. reinfection) between June and August 2021. Controls w...
Saved in:
Published in: | Public health (London) 2022-03, Vol.204, p.84-86 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c483t-cf37419f2eb25b145070eb401c87ac6d24ea8dc71a9f24c56d609851b07f6b013 |
---|---|
cites | cdi_FETCH-LOGICAL-c483t-cf37419f2eb25b145070eb401c87ac6d24ea8dc71a9f24c56d609851b07f6b013 |
container_end_page | 86 |
container_issue | |
container_start_page | 84 |
container_title | Public health (London) |
container_volume | 204 |
creator | Quattrocchi, Annalisa Tsioutis, Constantinos Demetriou, Anna Kyprianou, Theopisti Athanasiadou, Maria Silvestros, Valentinos Mamais, Ioannis Demetriou, Christiana A Theophanous, Fani Soteriou, Soteroulla Gregoriadou, Chryso Anastasiou, Eleni Kolios, Panayiotis Ηaralambous, Christos Gregoriou, Ioanna Kalakouta, Olga Nikolopoulos, Georgios |
description | We explored the effectiveness of COVID-19 vaccines in preventing reinfection in the Republic of Cyprus.
This was a matched case–control study (1:2).
Cases were adults with a first episode of SARS-CoV-2 infection in 2020 and a second episode (i.e. reinfection) between June and August 2021. Controls were adults with only one infection episode in 2020 (i.e. not reinfected). Matching was performed by age, gender, and week of diagnosis for the first episode. The reinfection date of a case was applied to the matched controls for estimating full or partial vaccination status. Cases and controls were classified as unvaccinated, partially vaccinated (i.e. vaccination series not completed or final dose received ≤14 days before the reinfection date), or fully vaccinated (i.e. final dose received >14 days before the reinfection date). Conditional logistic regression was performed to calculate odds ratios and 95% confidence intervals for full or partial vaccination, against no vaccination, between controls and cases.
This study showed that controls were more likely to be vaccinated (odds ratio for full vaccination: 5.51, 95% confidence interval: 2.43–12.49) than cases.
This finding answers a pressing question of the public and supports the offer of vaccination to people with previous SARS-CoV-2 infection. |
doi_str_mv | 10.1016/j.puhe.2022.01.008 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8769923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0033350622000099</els_id><sourcerecordid>2649760323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-cf37419f2eb25b145070eb401c87ac6d24ea8dc71a9f24c56d609851b07f6b013</originalsourceid><addsrcrecordid>eNp9kc-KFDEQh4Mo7rj6Ah4k4MVLj5U_nXSLCMuwq8KCsKteQzpd7WTs6cwm3QNz8x32DX0S08y6qAchkEN99VFVP0KeM1gyYOr1Zrmb1rjkwPkS2BKgekAWTGpVlIqph2QBIEQhSlAn5ElKGwDgWpSPyYkoWS1A8AXpzrsO3UhDR_fWOT_Y0YeB5nd9dnVdrMLXgtOIfpipuRJ9-v6GWupswp8_bl0Yxhh6msapPVA_0HGN9Ap3U9N7N1tXh12c0lPyqLN9wmd3_yn5cnH-efWhuPz0_uPq7LJwshJj4TqhJas7jg0vGyZL0ICNBOYqbZ1quURbtU4zmxnpStUqqKuSNaA71QATp-Td0ZsH2GLrME9ne7OLfmvjwQTrzd-Vwa_Nt7A3lVZ1zUUWvLoTxHAzYRrN1ieHfW8HDFMyXAnOZF1rmdGX_6CbMMUhr5cpWWuVDzwL-ZFyMaQUsbsfhoGZYzQbM8do5hgNMJNjzE0v_lzjvuV3bhl4ewQwH3PvMZrkPA4OWx9zUKYN_n_-X8tArws</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649760323</pqid></control><display><type>article</type><title>Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Elsevier</source><creator>Quattrocchi, Annalisa ; Tsioutis, Constantinos ; Demetriou, Anna ; Kyprianou, Theopisti ; Athanasiadou, Maria ; Silvestros, Valentinos ; Mamais, Ioannis ; Demetriou, Christiana A ; Theophanous, Fani ; Soteriou, Soteroulla ; Gregoriadou, Chryso ; Anastasiou, Eleni ; Kolios, Panayiotis ; Ηaralambous, Christos ; Gregoriou, Ioanna ; Kalakouta, Olga ; Nikolopoulos, Georgios</creator><creatorcontrib>Quattrocchi, Annalisa ; Tsioutis, Constantinos ; Demetriou, Anna ; Kyprianou, Theopisti ; Athanasiadou, Maria ; Silvestros, Valentinos ; Mamais, Ioannis ; Demetriou, Christiana A ; Theophanous, Fani ; Soteriou, Soteroulla ; Gregoriadou, Chryso ; Anastasiou, Eleni ; Kolios, Panayiotis ; Ηaralambous, Christos ; Gregoriou, Ioanna ; Kalakouta, Olga ; Nikolopoulos, Georgios</creatorcontrib><description>We explored the effectiveness of COVID-19 vaccines in preventing reinfection in the Republic of Cyprus.
This was a matched case–control study (1:2).
Cases were adults with a first episode of SARS-CoV-2 infection in 2020 and a second episode (i.e. reinfection) between June and August 2021. Controls were adults with only one infection episode in 2020 (i.e. not reinfected). Matching was performed by age, gender, and week of diagnosis for the first episode. The reinfection date of a case was applied to the matched controls for estimating full or partial vaccination status. Cases and controls were classified as unvaccinated, partially vaccinated (i.e. vaccination series not completed or final dose received ≤14 days before the reinfection date), or fully vaccinated (i.e. final dose received >14 days before the reinfection date). Conditional logistic regression was performed to calculate odds ratios and 95% confidence intervals for full or partial vaccination, against no vaccination, between controls and cases.
This study showed that controls were more likely to be vaccinated (odds ratio for full vaccination: 5.51, 95% confidence interval: 2.43–12.49) than cases.
This finding answers a pressing question of the public and supports the offer of vaccination to people with previous SARS-CoV-2 infection.</description><identifier>ISSN: 0033-3506</identifier><identifier>EISSN: 1476-5616</identifier><identifier>DOI: 10.1016/j.puhe.2022.01.008</identifier><identifier>PMID: 35193032</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Adults ; Case-Control Studies ; Confidence intervals ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Cyprus - epidemiology ; Humans ; Immunization ; Infections ; Medical diagnosis ; Reinfection ; Risk management ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Short Communication ; Statistical analysis ; Vaccination ; Vaccines</subject><ispartof>Public health (London), 2022-03, Vol.204, p.84-86</ispartof><rights>2022 The Royal Society for Public Health</rights><rights>Copyright © 2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Mar 2022</rights><rights>2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. 2022 The Royal Society for Public Health</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-cf37419f2eb25b145070eb401c87ac6d24ea8dc71a9f24c56d609851b07f6b013</citedby><cites>FETCH-LOGICAL-c483t-cf37419f2eb25b145070eb401c87ac6d24ea8dc71a9f24c56d609851b07f6b013</cites><orcidid>0000-0002-7865-8529 ; 0000-0003-4002-2880 ; 0000-0002-5764-6721</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902,30976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35193032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quattrocchi, Annalisa</creatorcontrib><creatorcontrib>Tsioutis, Constantinos</creatorcontrib><creatorcontrib>Demetriou, Anna</creatorcontrib><creatorcontrib>Kyprianou, Theopisti</creatorcontrib><creatorcontrib>Athanasiadou, Maria</creatorcontrib><creatorcontrib>Silvestros, Valentinos</creatorcontrib><creatorcontrib>Mamais, Ioannis</creatorcontrib><creatorcontrib>Demetriou, Christiana A</creatorcontrib><creatorcontrib>Theophanous, Fani</creatorcontrib><creatorcontrib>Soteriou, Soteroulla</creatorcontrib><creatorcontrib>Gregoriadou, Chryso</creatorcontrib><creatorcontrib>Anastasiou, Eleni</creatorcontrib><creatorcontrib>Kolios, Panayiotis</creatorcontrib><creatorcontrib>Ηaralambous, Christos</creatorcontrib><creatorcontrib>Gregoriou, Ioanna</creatorcontrib><creatorcontrib>Kalakouta, Olga</creatorcontrib><creatorcontrib>Nikolopoulos, Georgios</creatorcontrib><title>Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus</title><title>Public health (London)</title><addtitle>Public Health</addtitle><description>We explored the effectiveness of COVID-19 vaccines in preventing reinfection in the Republic of Cyprus.
This was a matched case–control study (1:2).
Cases were adults with a first episode of SARS-CoV-2 infection in 2020 and a second episode (i.e. reinfection) between June and August 2021. Controls were adults with only one infection episode in 2020 (i.e. not reinfected). Matching was performed by age, gender, and week of diagnosis for the first episode. The reinfection date of a case was applied to the matched controls for estimating full or partial vaccination status. Cases and controls were classified as unvaccinated, partially vaccinated (i.e. vaccination series not completed or final dose received ≤14 days before the reinfection date), or fully vaccinated (i.e. final dose received >14 days before the reinfection date). Conditional logistic regression was performed to calculate odds ratios and 95% confidence intervals for full or partial vaccination, against no vaccination, between controls and cases.
This study showed that controls were more likely to be vaccinated (odds ratio for full vaccination: 5.51, 95% confidence interval: 2.43–12.49) than cases.
This finding answers a pressing question of the public and supports the offer of vaccination to people with previous SARS-CoV-2 infection.</description><subject>Adult</subject><subject>Adults</subject><subject>Case-Control Studies</subject><subject>Confidence intervals</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Cyprus - epidemiology</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Medical diagnosis</subject><subject>Reinfection</subject><subject>Risk management</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Short Communication</subject><subject>Statistical analysis</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0033-3506</issn><issn>1476-5616</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNp9kc-KFDEQh4Mo7rj6Ah4k4MVLj5U_nXSLCMuwq8KCsKteQzpd7WTs6cwm3QNz8x32DX0S08y6qAchkEN99VFVP0KeM1gyYOr1Zrmb1rjkwPkS2BKgekAWTGpVlIqph2QBIEQhSlAn5ElKGwDgWpSPyYkoWS1A8AXpzrsO3UhDR_fWOT_Y0YeB5nd9dnVdrMLXgtOIfpipuRJ9-v6GWupswp8_bl0Yxhh6msapPVA_0HGN9Ap3U9N7N1tXh12c0lPyqLN9wmd3_yn5cnH-efWhuPz0_uPq7LJwshJj4TqhJas7jg0vGyZL0ICNBOYqbZ1quURbtU4zmxnpStUqqKuSNaA71QATp-Td0ZsH2GLrME9ne7OLfmvjwQTrzd-Vwa_Nt7A3lVZ1zUUWvLoTxHAzYRrN1ieHfW8HDFMyXAnOZF1rmdGX_6CbMMUhr5cpWWuVDzwL-ZFyMaQUsbsfhoGZYzQbM8do5hgNMJNjzE0v_lzjvuV3bhl4ewQwH3PvMZrkPA4OWx9zUKYN_n_-X8tArws</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Quattrocchi, Annalisa</creator><creator>Tsioutis, Constantinos</creator><creator>Demetriou, Anna</creator><creator>Kyprianou, Theopisti</creator><creator>Athanasiadou, Maria</creator><creator>Silvestros, Valentinos</creator><creator>Mamais, Ioannis</creator><creator>Demetriou, Christiana A</creator><creator>Theophanous, Fani</creator><creator>Soteriou, Soteroulla</creator><creator>Gregoriadou, Chryso</creator><creator>Anastasiou, Eleni</creator><creator>Kolios, Panayiotis</creator><creator>Ηaralambous, Christos</creator><creator>Gregoriou, Ioanna</creator><creator>Kalakouta, Olga</creator><creator>Nikolopoulos, Georgios</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><general>The Royal Society for Public Health. Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7865-8529</orcidid><orcidid>https://orcid.org/0000-0003-4002-2880</orcidid><orcidid>https://orcid.org/0000-0002-5764-6721</orcidid></search><sort><creationdate>20220301</creationdate><title>Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus</title><author>Quattrocchi, Annalisa ; Tsioutis, Constantinos ; Demetriou, Anna ; Kyprianou, Theopisti ; Athanasiadou, Maria ; Silvestros, Valentinos ; Mamais, Ioannis ; Demetriou, Christiana A ; Theophanous, Fani ; Soteriou, Soteroulla ; Gregoriadou, Chryso ; Anastasiou, Eleni ; Kolios, Panayiotis ; Ηaralambous, Christos ; Gregoriou, Ioanna ; Kalakouta, Olga ; Nikolopoulos, Georgios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-cf37419f2eb25b145070eb401c87ac6d24ea8dc71a9f24c56d609851b07f6b013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Case-Control Studies</topic><topic>Confidence intervals</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Cyprus - epidemiology</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Medical diagnosis</topic><topic>Reinfection</topic><topic>Risk management</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Short Communication</topic><topic>Statistical analysis</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quattrocchi, Annalisa</creatorcontrib><creatorcontrib>Tsioutis, Constantinos</creatorcontrib><creatorcontrib>Demetriou, Anna</creatorcontrib><creatorcontrib>Kyprianou, Theopisti</creatorcontrib><creatorcontrib>Athanasiadou, Maria</creatorcontrib><creatorcontrib>Silvestros, Valentinos</creatorcontrib><creatorcontrib>Mamais, Ioannis</creatorcontrib><creatorcontrib>Demetriou, Christiana A</creatorcontrib><creatorcontrib>Theophanous, Fani</creatorcontrib><creatorcontrib>Soteriou, Soteroulla</creatorcontrib><creatorcontrib>Gregoriadou, Chryso</creatorcontrib><creatorcontrib>Anastasiou, Eleni</creatorcontrib><creatorcontrib>Kolios, Panayiotis</creatorcontrib><creatorcontrib>Ηaralambous, Christos</creatorcontrib><creatorcontrib>Gregoriou, Ioanna</creatorcontrib><creatorcontrib>Kalakouta, Olga</creatorcontrib><creatorcontrib>Nikolopoulos, Georgios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Public health (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quattrocchi, Annalisa</au><au>Tsioutis, Constantinos</au><au>Demetriou, Anna</au><au>Kyprianou, Theopisti</au><au>Athanasiadou, Maria</au><au>Silvestros, Valentinos</au><au>Mamais, Ioannis</au><au>Demetriou, Christiana A</au><au>Theophanous, Fani</au><au>Soteriou, Soteroulla</au><au>Gregoriadou, Chryso</au><au>Anastasiou, Eleni</au><au>Kolios, Panayiotis</au><au>Ηaralambous, Christos</au><au>Gregoriou, Ioanna</au><au>Kalakouta, Olga</au><au>Nikolopoulos, Georgios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus</atitle><jtitle>Public health (London)</jtitle><addtitle>Public Health</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>204</volume><spage>84</spage><epage>86</epage><pages>84-86</pages><issn>0033-3506</issn><eissn>1476-5616</eissn><abstract>We explored the effectiveness of COVID-19 vaccines in preventing reinfection in the Republic of Cyprus.
This was a matched case–control study (1:2).
Cases were adults with a first episode of SARS-CoV-2 infection in 2020 and a second episode (i.e. reinfection) between June and August 2021. Controls were adults with only one infection episode in 2020 (i.e. not reinfected). Matching was performed by age, gender, and week of diagnosis for the first episode. The reinfection date of a case was applied to the matched controls for estimating full or partial vaccination status. Cases and controls were classified as unvaccinated, partially vaccinated (i.e. vaccination series not completed or final dose received ≤14 days before the reinfection date), or fully vaccinated (i.e. final dose received >14 days before the reinfection date). Conditional logistic regression was performed to calculate odds ratios and 95% confidence intervals for full or partial vaccination, against no vaccination, between controls and cases.
This study showed that controls were more likely to be vaccinated (odds ratio for full vaccination: 5.51, 95% confidence interval: 2.43–12.49) than cases.
This finding answers a pressing question of the public and supports the offer of vaccination to people with previous SARS-CoV-2 infection.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>35193032</pmid><doi>10.1016/j.puhe.2022.01.008</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-7865-8529</orcidid><orcidid>https://orcid.org/0000-0003-4002-2880</orcidid><orcidid>https://orcid.org/0000-0002-5764-6721</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-3506 |
ispartof | Public health (London), 2022-03, Vol.204, p.84-86 |
issn | 0033-3506 1476-5616 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8769923 |
source | Applied Social Sciences Index & Abstracts (ASSIA); Elsevier |
subjects | Adult Adults Case-Control Studies Confidence intervals COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines Cyprus - epidemiology Humans Immunization Infections Medical diagnosis Reinfection Risk management SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Short Communication Statistical analysis Vaccination Vaccines |
title | Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T01%3A09%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20vaccination%20on%20SARS-CoV-2%20reinfection%20risk:%20a%20case%E2%80%93control%20study%20in%20the%20Republic%20of%20Cyprus&rft.jtitle=Public%20health%20(London)&rft.au=Quattrocchi,%20Annalisa&rft.date=2022-03-01&rft.volume=204&rft.spage=84&rft.epage=86&rft.pages=84-86&rft.issn=0033-3506&rft.eissn=1476-5616&rft_id=info:doi/10.1016/j.puhe.2022.01.008&rft_dat=%3Cproquest_pubme%3E2649760323%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c483t-cf37419f2eb25b145070eb401c87ac6d24ea8dc71a9f24c56d609851b07f6b013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2649760323&rft_id=info:pmid/35193032&rfr_iscdi=true |